Xbrane Biopharma AB (publ) (XBRANE) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to xBrain Biopharma Q2 Report 2026. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Martin Amark and CFO Jane Benyamin. Please go ahead. Hello, everybody. Welcome to our webcast in relation to the Q2 report 2026 of X-Bane Biopharma. As usually, I will go through an operational update of the quarter and then Jane will go through a financial update. We'll start off with Ximluci, our buy similar to Lucentis, which is on the market in Europe and commercialized by our commercialization partner Stada. Those of you who have followed us know the arrangement. We share the profit contribution 50-50 of the sales and it's currently launched across 24 countries in Europe and a few countries in the Middle East. And this is a sizeable market opportunity. We are addressing 5 billion euros steadily growing. although facing somewhat increasing competition in relation to biosimilars to ILEA gradually coming to the market in Europe as well as in the US. Looking at the current quarter, we are still at a market share around 7% from a volume perspective. And I mean, we're releasing this Q2 report quite early, so we haven't received the final data actually for the quarter in relation to units sold and so on and so forth. But 7% volume market share as of April 2026. What you can see from the financial figures in the report, we have resumed the shipments of the final goods to Stada during the quarter and that is expected to remain during the remaining quarters of the year. And accumulated, we have now profit sharing of 127 million Swedish crowns. We are also, as we've been discussing before, working intensively to reduce the production costs across a multitude ...